Stock market today: S&P 500 drops for fifth day as focus shifts to Powell’s speech
Investing.com - Truist Securities raised its price target on American Healthcare REIT , Inc (NYSE:AHR) to $44.00 from $38.00 on Monday, while maintaining a Buy rating on the stock. The new target sits within the broader analyst range of $37-$50, according to InvestingPro data, with the stock currently trading at $40.85 and showing remarkable momentum with a 120% return over the past year.
The price target increase follows strong second-quarter results and higher earnings guidance from the healthcare REIT, according to Truist Securities’ research note.
The new $44 price target implies an 11.5% total return potential, despite Truist’s projection of multiple contraction for the stock.
Truist Securities believes American Healthcare REIT is "extremely well positioned" both in terms of alignment with industry trends and due to company-specific characteristics and strategy.
The firm calculates that AHR has the second-best three-year normalized FFO PEG ratio in its six-company healthcare REIT coverage universe and the third-best five-year ratio, suggesting potential for dividend increases in coming years.
In other recent news, American Healthcare REIT reported strong second-quarter 2025 financial results, highlighted by a 27% increase in normalized funds from operations per share. The company also raised its full-year NFFO guidance, reflecting a positive outlook. Following these results, several analysts adjusted their price targets for the company. Truist Securities increased its price target to $44, citing the company’s favorable positioning and strong earnings guidance. RBC Capital also raised its price target to $45, maintaining an Outperform rating, and described the results as solid. JMP Securities followed suit, raising their target to $45 and noting that the company’s Core FFO per share exceeded expectations. These developments indicate a strong performance and positive sentiment among analysts regarding American Healthcare REIT’s future prospects.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.